Bio-Me

Executive Summary

Bio-Me is a Norwegian biotechnology company that has developed a proprietary Precision Microbiome Profiling (PMP™) platform, a high-throughput qPCR-based service enabling rapid, accurate, and reproducible microbiome analysis down to species and strain resolution. Founded in 2014 and headquartered in Oslo, the company serves academic researchers, pharmaceutical firms, and consumer health companies, aiming to bridge microbiome research with clinical diagnostics and therapeutic development. Its technology offers a cost-effective and scalable alternative to sequencing-based methods, positioning it as a key player in the growing microbiome diagnostics market. The company is privately held and has not disclosed funding rounds or valuation, but its focus on translating research into clinical applications suggests potential for strategic partnerships or future investment. With increasing interest in microbiome-based therapeutics and diagnostics, Bio-Me is well-placed to capitalize on demand for precise, reproducible profiling. Key near-term catalysts include new pharma collaborations, expansion into clinical diagnostic services, and potential funding to scale operations. The company's technology and market positioning support a moderate conviction in its growth trajectory.

Upcoming Catalysts (preview)

• Q3 2026New Pharmaceutical Collaboration for Microbiome-Based Therapeutic Development60% success
• Q4 2026Launch of Clinical Diagnostic Service for Gut Microbiome Profiling50% success
• Q1 2027Series A or Strategic Investment Round70% success